Saphenous Vein Graft Intervention  by Lee, Michael S. et al.
P
J
L
D
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 8 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 5 . 0 1 4STATE-OF-THE-ART PAPER
Saphenous Vein Graft Intervention
Michael S. Lee, MD,* Seung-Jung Park, MD,‡ David E. Kandzari, MD,§
Ajay J. Kirtane, MD, SM, William F. Fearon, MD,† Emmanouil S. Brilakis, MD, PHD,¶
aul Vermeersch, MD,# Young-Hak Kim, MD,‡ Ron Waksman, MD,**
ulinda Mehilli, MD,†† Laura Mauri, MD,‡‡ Gregg W. Stone, MD
os Angeles and Palo Alto, California; Seoul, South Korea; Atlanta, Georgia; New York, New York;
allas, Texas; Antwerp, Belgium; Washington, DC; Munich, Germany; and Boston, Massachusetts
Saphenous vein grafts are commonly used conduits for surgical revascularization of coronary arteries but
are associated with poor long-term patency rates. Percutaneous revascularization of saphenous vein grafts
is associated with worse clinical outcomes including higher rates of in-stent restenosis, target vessel revas-
cularization, myocardial infarction, and death compared with percutaneous coronary intervention of native
coronary arteries. Use of embolic protection devices is a Class I indication according to the American College of
Cardiology/American Heart Association guidelines to decrease the risk of distal embolization, no-reﬂow, and
periprocedural myocardial infarction. Nonetheless, these devices are underused in clinical practice. Various phar-
macological agents are available that may also reduce the risk of or mitigate the consequences of no-reﬂow.
Covered stents do not decrease the rates of periprocedural myocardial infarction and restenosis. Most available
evidence supports treatment with drug-eluting stents in this high-risk lesion subset to reduce angiographic and
clinical restenosis, although large, randomized trials comparing drug-eluting stents and bare-metal stents are
needed. (J Am Coll Cardiol Intv 2011;4:831–43) © 2011 by the American College of Cardiology FoundationThe long-term success of surgical coronary re-
vascularization is limited by accelerated athero-
sclerosis and intimal fibrosis of the saphenous
vein graft (SVG) after its use as a vascular conduit.
At 1 year, the incidence of 1 or more total SVG
occlusions has been reported to be as high as 41%
after on-pump bypass surgery (Table 1) (1–8). Be-
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832In this review, we describe the risk factors for complications
after SVG intervention and discuss the optimal procedural
treatment strategies regarding periprocedural anticoagulation,
choice of stent, and measures to mitigate the risks of distal
embolization.
Pathobiology of SVG
SVG intervention remains technically challenging and is asso-
ciated with higher rates of periprocedural myocardial infarc-
tion, in-hospital mortality, restenosis, and occlusion compared
with PCI of native coronary arteries largely because of the
friable, degenerated atheromatous and thrombotic debris that
develop when SVGs deteriorate (15). Progression of disease
outside the stented segment can also lead to high rates of target
vessel revascularization. Therefore,
treatment of native coronary artery
lesions is preferred to treatment of
degenerated SVG if feasible.
A recognized consequence of
SVG intervention is distal emboli-
zation of atheroembolic debris with
decreased epicardial and microvas-
cular perfusion due to capillary
plugging and vasospasm from the
release of neurohumoral factors
such as serotonin. Distal emboliza-
tion may result in the slow or no-
reflow phenomenon in approxi-
mately 10% to 15% of cases and is
associated with periprocedural an-
gina and ischemic ST-segment
changes (16). In such instances,
subsequent myocardial infarction
occurs in 31% of patients and in-
hospital mortality increases 10-fold
(17). However, distal embolization
remains difficult to predict (18).
Predictors of
Adverse Clinical Events
Periprocedural creatine kinase-myocardial band (CK-MB)
elevation after successful SVG intervention was common
(ranging from 15% to 47%) (19,20). The use of embolic
protection devices has been systematically associated with
periprocedural myocardial infarction rates 10% (21,22).
Differences in myocardial infarction rates between studies
may also be explained by differences in myocardial infarction
definitions, the sensitivity and frequency of biomarker
measurement, and the complexity of SVG disease studied.
Hong et al. (19) reported that 15% of patients experienced
major CK-MB release exceeding 5 the upper limit of
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
FDA  U.S. Food and Drug
Administration
FFR  fractional flow
reserve
HR  hazard ratio
MACE  major adverse
cardiac event(s)
OR  odds ratio
PCI  percutaneous
coronary intervention
PTFE 
polytetrafluorethylene
SVG  saphenous vein graft
TIMI  Thrombolysis In
Myocardial Infarctionnormal following SVG PCI. Although the association of hperiprocedural myonecrosis and late clinical outcomes is
controversial among patients undergoing native vessel PCI,
even minor elevations of CK-MB (1 to 5 normal) after
SVG intervention have been associated with increased
mortality at 1 year (6.5% vs. 4.8%, p  0.05), with CK-MB
release exceeding 5 the upper limit of normal increasing
1-year mortality by 144%. Multivariate analysis revealed
that major CK-MB release after SVG intervention was a
powerful independent predictor of late mortality (odds ratio
[OR]: 3.3, 95% confidence interval [CI]: 1.7 to 6.2).
Lesion length, greater angiographic degeneration of
SVGs, and larger estimated plaque volume have been
identified as predictors of 30-day major adverse cardiac
events (MACE) after SVG intervention (23–25). This may
be explained by the fact that the greater the amount of
plaque, the greater the likelihood of distal embolization
after intervention, leading to myocardial infarction.
Patient sex also appears to be a significant predictor of
outcomes after SVG intervention. Women had higher 30-day
cumulative mortality rates (4.4% vs. 1.9%, p 0.02) compared
with men (26). Furthermore, women had a higher incidence of
vascular complications (12% vs. 7.3%, p  0.006) and post-
procedural acute renal failure (8.1% vs. 4%, p  0.02).
In a 172-patient study of SVG intervention with drug-
eluting stents (DES), chronic renal insufficiency (serum
creatinine 1.5 mg/dl) was the only significant predictor of
1-year MACE (hazard ratio [HR]: 2.2, 95% CI: 1.1 to 4.3,
p 0.03) (27). A trend was also present toward higher rates
f target vessel revascularization in the renal insufficiency
roup (21.8% vs. 10.3%, HR: 2.42, 95% CI: 0.94 to 6.24,
 0.059). Similar results were observed with bare-metal
tents (BMS). Overall mortality rates were significantly
Table 1. Saphenous Vein Graft Occlusion Rates From Selected Studies
Study/First
Author (Ref. #) 1 Year 5 Years 10 Years
PRAGUE-4 (1) 41 (per patient on-pump) NA NA
51 (per patient off-pump) NA NA
PREVENT IV (2) 41.7 (per patient) NA NA
26.6 (per SVG) NA NA
Fitzgibbon et al. (3) 19 (per SVG) 25 (per SVG) 40 (per SVG)
RIGOR (4) 31 (per patient) NA NA
19 (per SVG) NA NA
Halabi et al. (5) 39.3 (per patient) NA NA
Khot et al. (6) 30.1 (SVG) NA NA
ROOBY (7) 28.7 (per patient on-pump) NA NA
36.5 (per patient off-pump) NA NA
Goldman et al. (8) 20 (per patient) 31 (per patient) 39 (per patient)
Values are %.
NA  not available; PREVENT IV  Project of Ex Vivo Vein Graft Engineering via Transfection;
RIGOR  Reduction in Graft Occlusion Rates; ROOBY  Veterans Affairs Randomized On/Off
Bypass study.igher in patients with renal insufficiency (p  0.001) (28).
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833Decision to Perform
SVG Percutaneous Intervention
The decision regarding whether or not to intervene in a
diseased SVG should be guided by the patient’s symptoms,
angiographic evidence of a significant stenosis, and nonin-
vasive evidence of myocardial ischemia in the region sub-
tended by the SVG. Even though the role of intravascular
ultrasound or fractional flow reserve (FFR) measurement in
assessing the significance of SVG disease has not been well
studied, FFR can be performed in an SVG in a similar
fashion as in a native coronary vessel. The pressure sensor
should be positioned in the distal two-thirds of the native
vessel so the entire conduit can be interrogated. Intravenous
adenosine should be administered to induce hyperemia and
a slow pullback of the pressure wire can be performed to
distinguish focal from diffuse disease. Prospective validation
of an FFR cutoff value of 0.75 to 0.80 to detect hemody-
namically significant SVG stenosis has not been performed.
Nonetheless, this cutoff is generally used in clinical practice.
Of note, however, SVG disease progresses more rapidly
than native coronary artery disease, and the safety of
deferring intervention on a diseased SVG with a nonisch-
emic FFR has not been studied.
Adverse clinical events occurring12 months after initial
SVG intervention most frequently resulted from disease
progression at untreated intermediate lesions (29). Because
SVG disease can progress rapidly, some have advocated
prophylactically stenting intermediate SVG lesions as op-
posed to continuing with medical therapy alone. In the
small (57-patient) randomized VELETI (Treatment of
Moderate Vein Graft Lesions With Paclitaxel Drug-
Eluting Stents) trial, the 1- and 3-year MACE rates were
significantly lower in patients in whom moderate (30% to
60%) SVG stenoses were treated with paclitaxel-eluting
stents compared with patients who received medical treat-
ment (3% vs. 19%, p  0.09 at 1 year, and 3% vs. 26%, p 
0.02 at 3 years), thus supporting a strategy of plaque sealing
with DES in moderate nonangiographically significant le-
sions in degenerated SVGs at increased risk for disease
progression and adverse clinical events (30,31). However,
this trial was an imaging study that was not powered for
clinical endpoints. The 450-patient VELETI II (Sealing
Moderate Coronary Saphenous Vein Graft Lesions With
Paclitaxel-Eluting Stents) trial (NCT01223443) is currently
randomizing patients with intermediate SVG lesions to
either SVG intervention with paclitaxel-eluting stents ver-
sus medical therapy alone and has a primary clinical rather
than angiographic endpoint.
Treatment of Occluded SVGs
In a study of 34 patients with chronic total SVG occlusion
for which percutaneous revascularization was attempted,successful recanalization with stent implantation was low
(68%) (32). At a median follow-up of 18 months, the rates
of in-stent restenosis and target vessel revascularization were
unacceptably high (68% and 61%, respectively) in patients
who underwent successful stenting despite a high use of
DES (95%). Given the poor short- and long-term outcomes
of percutaneous revascularization in chronic total occlusion
of SVGs, percutaneous revascularization should rarely be
considered except for acute occlusion in the setting of
myocardial infarction. Instead, attempts to recanalize the
native coronary artery are preferred if feasible.
Antithrombin and Antiplatelet Therapy
The preferred parenteral antithrombotic therapy during
SVG intervention has not been studied in a dedicated,
prospective clinical trial. Several studies demonstrated that
the role of glycoprotein IIb/IIIa antagonists in SVG inter-
vention is limited given their failure to demonstrate a
reduction in periprocedural myocardial infarction (33–35).
However, 1 post hoc analysis demonstrated a trend toward
improved procedural success when glycoprotein IIb/IIIa
antagonists were used in conjunction with filter-based
embolic protection (p  0.058) but the MACE was not
different at 30 days (36). In a single center, retrospective
observational study, bivalirudin was associated with a sig-
nificant reduction in major CK-MB elevation and a trend
toward lower in-hospital non–Q-wave myocardial infarc-
tion, repeat revascularization, and vascular complications
compared with unfractionated heparin (37). In the subset of
329 patients who underwent SVG intervention in ACUITY
(Acute Catheterization and Urgent Intervention Triage
Strategy Trial) (38), the rates of ischemic bleeding and net
clinical endpoints were similar with bivalirudin mono-
therapy, bivalirudin plus a glycoprotein IIb/IIIa antagonist,
and heparin plus a glycoprotein IIb/IIIa antagonist. Minor
bleeding complications were lower with bivalirudin alone
compared with heparin plus a glycoprotein IIb/IIIa antag-
onist (26% vs. 38%, p  0.05). Thus, bivalirudin may offer
a safety advantage over other antithrombotic regimens, with
equal or greater suppression of adverse ischemic events,
although this conclusion is not definitive in the absence of
an adequately powered randomized trial.
Stent Type Selection
Bare-metal stents. The SAVED (Saphenous Vein de Novo)
trial reported that compared with balloon angioplasty, BMS
were associated with higher procedural success (92% vs.
69%, p 0.001), a trend toward a reduction in angiographic
restenosis (36% vs. 47%, p  0.11), and lower MACE
through 240 days (26% vs. 38%, p  0.04) (39). Since the
SAVED report, the overwhelming majority of SVG inter-
vention has been performed with stents, and subsequent
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834randomized trials have compared BMS with covered stents
or DES (Table 2).
Covered stents. Stents covered with a mesh, most com-
monly polytetrafluorethylene (PTFE), have a theoretical
advantage over conventional stents because they may “trap”
friable atheroemboli and prevent distal embolization and
serve as a smooth-muscle cell barrier and therefore decrease
restenosis. However, 3 prospective randomized trials failed
to demonstrate benefit with covered stents. SYMBIOT III
(A Prospective, Randomized Trial of a Self-Expanding
PTFE Stent Graft During SVG Intervention–Late Results)
(40) compared the self-expandable PTFE-covered nitinol
Symbiot stent (Boston Scientific Corp., Natick, Massachu-
setts) with BMS. At 8 months, the incidence of MACE
between the Symbiot group and BMS was similar (30.6% vs.,
26.6%, p  0.43). A trend toward increased target lesion
revascularization with the Symbiot stent was also observed
(23.5% vs. 15.6%, p 0.055). The RECOVERS (Randomized
Evaluation of Polytetrafluoroethylene-Covered Stent in Sa-
phenous Vein Grafts) trial (41) randomized 301 patients to
treatment with either the PTFE-covered JoStent balloon-
expandable stent (Jomed International AB, Helsingborg, Swe-
den) or BMS. The PTFE group had a higher incidence of
30-day MACE (10.9% vs. 4.1%, p 0.047), mainly attributed
to increased incidence of myocardial infarction (10.3% vs.
3.4%, p 0.037). At 6 months, the restenosis rate was similar
between the 2 groups (24.2% vs. 24.8%, p  0.237), and the
MACE rate was not different (23.1% vs. 15.9%, p  0.153).
Table 2. Clinical Outcomes of Randomized Stent Trials in Saphenous Vein
SYMBIOT III BARRICADE RECOVERS
PTFE BMS p Value PTFE BMS p Value PTFE BMS p
MACE
1 yr 30.6 26.6 0.43 39.2* 28.0* 0.07 23.1† 15.9†
3 yrs NA NA NA 60.2 37.0 0.001 NA NA
5 yrs NA NA NA 68.3 51.8 0.007 NA NA
Death
1 yr 2.6‡ 4.7‡ 0.29 7.0 5.0 0.51 2.6† 2.8†
3 yrs NA NA NA 18.8 11.2 0.13 NA NA
5 yrs NA NA NA 29.8 22.3 0.20 NA NA
MI
1 yr 9.2 10.9 0.61 14.2 11.3 0.53 14.1† 5.5†
3 yrs NA NA NA 21.0 14.1 0.21 NA NA
5 yrs NA NA NA 26.2 17.4 0.16 NA NA
TLR
1 yr 23.5 15.6 0.06 28.2 21.1 0.46 9.6† 8.3†
3 yrs NA NA NA 37.4 21.8 0.02 NA NA
5 yrs NA NA NA 43.9 29.6 0.04 NA NA
*Target vessel failure (composite of all-cause death, MI, or clinically driven target vessel revasculariz
BARRICADE  Barrier Approach to Restenosis: Restrict Intima to Curtail Adverse Events study;
Drug-Eluting Stents Versus Bare Metal Stents for the Reduction of Restenosis in Bypass Graft
polytetrafluorethylene; RECOVERS  Randomized Evaluation of Polytetrafluoroethylene-Cove
Cypher Sirolimus-Eluting Stent; SOS Stenting of Saphenous Vein Grafts; SYMBIOT III A ProsTLR  target lesion revascularization.The BARRICADE (Barrier Approach to Restenosis: Restrict
Intima to Curtail Adverse Events) trial (42) also randomized
243 patients to treatment with either the PTFE-covered
JoStent balloon-expandable stent (Jomed) or BMS. At 5-year
follow-up, target vessel failure was higher in the JoStent group
than in the BMS group (68.3% vs. 51.8%, p  0.007),
emphasizing the dismal long-term prognosis of SVG treat-
ment with either BMS or covered stents.
Two other covered stents have shown promise in the
treatment of degenerated SVGs although long-term head-
to-head comparison data with BMS are lacking. In the
SESAME first in human trial (43), 20 patients who
underwent SVG intervention with a novel nanosynthesized,
membrane-covered self-expanding superelastic all-metal
endoprosthesis stent (SESAME stent, Advanced Biopros-
thetic Surfaces, Ltd., San Antonio, Texas) had a 0% rate of
MACE at 30 days. At 9 months, the MACE rate was 14%
(3 patients underwent repeat intervention: 1 underwent
target lesion revascularization for restenosis at the overlap of
2 stents and 2 underwent target vessel revascularization for
lesions outside the stented segment). Preliminary results
with the MGuard stent (InspireMD, Tel Aviv, Israel), a
BMS with a polymeric net attached to its surface, demon-
strated favorable early performance in a study that included
16 patients who underwent SVG intervention with no
angiographic/procedural complications, and no adverse
events up to 30 days (44).
SOS RRISC ISAR-CABG
PES BMS p Value SES BMS p Value DES BMS p Value
37 49 0.20 15.8† 29.7† 0.15 15.4 22.1 0.03
54 77 0.49 58 41 0.13 NA NA NA
NA NA NA NA NA NA NA NA NA
12 5 0.27 2.6† 0† 0.99 5.2 4.7 0.82
24 13 0.19 29 0 0.001 NA NA NA
NA NA NA NA NA NA NA NA NA
15 31 0.10 2.6† 0† 0.99 4.2 6.0 0.27
17 46 0.01 18 5 0.15 NA NA NA
NA NA NA NA NA NA NA NA NA
5 28 0.003 5.3† 21.6† 0.05 7.2 13.1 0.02
10 41 0.004 24 30 0.55 NA NA NA
NA NA NA NA NA NA NA NA NA
†6 months. ‡Cardiac death.
bare-metal stent(s); DES  drug-eluting stent(s); ISAR-CABG  Prospective, Randomized Trial of
E  major adverse cardiac event(s); MI  myocardial infarction; NA  not available; PTFE 
nt in Saphenous Vein Grafts; RRISC  Reduction of Restenosis in Saphenous Vein Grafts With
, Randomized Trial of a Self-Expanding PTFE Stent Graft During SVG Intervention–Late Results;Grafts
Value
0.15
NA
NA
0.92
NA
NA
0.02
NA
NA
0.84
NA
NA
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835Drug-eluting stents. The RRISC (Reduction of Restenosis
n Saphenous Vein Grafts With Cypher Sirolimus-Eluting
tent) trial (21), which included 75 patients, reported that
irolimus-eluting stents (Cordis, Warren, New Jersey) re-
uced late loss, the binary restenosis rate, and target lesion
nd vessel revascularization compared with BMS at
-month follow-up. However, the DELAYED RRISC
Death and Events at Long-Term Follow-Up Analysis:
xtended Duration of the Reduction of Restenosis in
aphenous Vein Grafts With Cypher Stent) study (45),
hich was a post hoc analysis of RRISC trial at 3 years,
eported similar rates of target vessel revascularization.
lthough statistically underpowered for clinical outcomes,
ignificantly higher all-cause mortality at 3 years was re-
orted with sirolimus-eluting stents compared with BMS.
he SOS (Stenting of Saphenous Vein Grafts) trial (22),
hich included 80 patients randomized to either paclitaxel-
luting stents (Taxus, Boston Scientific Corp., Maple
rove, Minnesota) or BMS, demonstrated a significant
eduction in MACE driven by lower target lesion revascu-
arization rates with paclitaxel-eluting stents without in-
reased death or myocardial infarction through nearly 3-year
ollow-up (46). The primary endpoint of these 2 small trials
as angiographic restenosis, and the results showed similar
ngiographic restenosis rates at 6- (RRISC) and 12-month
SOS) follow-up but higher mortality at long-term
ollow-up in the RRISC trial. ISAR-CABG (Prospective,
andomized Trial of Drug-Eluting Stents Versus Bare
etal Stents for the Reduction of Restenosis in Bypass
rafts), which randomized 610 patients with diseased SVGs
o DES and BMS, the primary endpoint of MACE at 1-year
ost index PCI was lower in the DES group than in the BMS
roup (15.4% vs. 22.1%, p  0.03) and was mainly driven by
nearly 50% relative reduction in the risk of target lesion
evascularization (7.2% vs. 13.1%, p  0.02), with nonsignif-
cant differences in mortality (47).
A meta-analysis comparing DES with BMS in SVG
ntervention (which also included nonrandomized studies)
as also reported lower mortality, MACE, target lesion
evascularization, and target vessel revascularization without
ncreased risk of myocardial infarction or stent thrombosis
48). Eight other meta-analyses comparing DES with BMS
n SVG intervention have demonstrated consistent results of
mproved efficacy with DES and no significant safety hazard
48–55).
Two ongoing trials are comparing DES with BMS in
VGs: 1) BASKETSAVAGE (Basel Stent Kosten Effek-
ivitäts Trial–Saphenous Venous Graft Angioplasty Using
lycoprotein IIb/IIIa Receptor Inhibitors and Drug-
luting Stents) (NCT00595647); and 2) the Veterans’
ffairs Cooperative Study #571, DIVA (Drug Eluting
tents Versus Bare-Metal Stents in Saphenous Vein Graft
ngioplasty) trials (NCT01121224). (Choice of DES in SVG. In a multicenter analysis of 172
eal-world patients comparing first-generation DES, SVG
ntervention with sirolimus- and paclitaxel-eluting stents
esulted in nonsignificant differences in survival (HR: 1.28,
5% CI: 0.39 to 4.25, p  0.69) and target vessel revascu-
arization (HR: 2.54, 95% CI: 0.84 to 7.72, p  0.09) (56).
utcomes comparing second-generation stents in SVG
ntervention are not yet available; the SOS-Xience V (Pro-
pective Evaluation of the Xience V Everolimus-Eluting
tent in Saphenous Vein Graft Atherosclerosis: The Stent-
ng of Saphenous Vein Grafts Xience V Angiographic
tudy) (NCT00911976) will provide initial results with the
verolimus-eluting stent in 2011.
VG Intervention Technique
Pre-dilation versus direct stenting. As opposed to pre-
ilation with balloon angioplasty, direct stenting has the
otential benefit of trapping debris and decreasing distal
mbolization that may occur from repeated balloon infla-
ions. In a registry of unselected patients who underwent
VG intervention, direct stenting was associated with a
early 50% reduction in CK-MB elevations greater than 4
ormal (13.6% vs. 23%, p  0.12), overall lower maximum
CK-MB release (9.5 vs. 19.6, p  0.001), and fewer
non–Q-wave myocardial infarctions (10.7% vs. 18.4%, p 
0.02) (57). A prospective randomized trial is needed to
determine whether pre-dilation versus direct stenting is
effective in reducing distal embolization.
Small stent diameter. In a study of 209 SVG lesions treated
ith DES, Hong et al. (58) examined the outcomes of 3
roups according to the ratio of the stent diameter to the
verage intravascular ultrasound reference lumen diameter
group I: 0.89, group II: 0.9 to 1.0, and group III: 1.0).
laque intrusion volume as defined as the amount of tissue
xtrusion through the stent struts after SVG intervention
as smallest in group I (group I: 0.25  0.68 mm3, group II:
0.40 0.68 mm3, and group III: 0.75 1.34 mm3; p 0.007).
he incidence of CK-MB elevation 3 normal was 6% in
roup I, 9% in group II, and 19% in group III (p  0.03)
ithout an increase in clinical events at 1 year. The
ncidence of 1-year target lesion revascularization (group I:
3%, group II: 9%, and group III: 15%; p  0.5) and target
essel revascularization (group I: 13%, group II: 13%, and
roup III: 15%; p  0.9) was similar. While the concept of
ndersized stent selection to reduce distal embolization is
ntriguing, such a method must be balanced by theoretically
ossibly higher rates of restenosis and stent thrombosis.
herefore, a prospective, randomized study is required to
onfirm the theoretical benefits of this technique.
Embolic protection devices. Distal embolization is common
n SVG interventions. Particulate debris has been retrieved
rom as many as 91% of distal embolic protection devices
59). Despite the class I American College of Cardiology/
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836American Heart Association PCI guidelines’ recommenda-
tion for the use of embolic protection devices in SVG
intervention, overall adoption remains low (60). In the
American College of Cardiology National Cardiovascular
Data CathPCI Registry, embolic protection was only used
in 23% of patients (10). Currently available embolic protec-
tion devices include occlusion balloon plus aspiration sys-
tems, distal filter-based devices, and proximal flow interrup-
tion catheters (Table 3) (61).
Distal balloon occlusion devices. Distal balloon occlusion
of the SVG beyond the lesion creates a stagnant column
of blood that may prevent plaque embolization into the
myocardial bed (Fig. 1). Upon the conclusion of the
intervention, the blood with contained debris can be
removed by an aspiration catheter before occlusion bal-
Table 3. Comparison of Different Embolic Protection Devices
Distal Filter
Distal
Balloon
Occlusion
Proximal
Balloon
Occlusion
Complete occlusion No Yes Yes
Allows perfusion Yes No No
Ischemia No Yes Yes
Maintenance of antegrade blood ﬂow
during intervention
Yes No No
Protects before crossing lesion No No Yes
Crossing proﬁle High (3.2-F)* Low (2.7)† NA
Maneuverability Reduced Good Good
Ease of use Simple Complex Complex
Capture of smaller particles No Yes Yes
Capture of neurohormonal substances No Yes Yes
*FilterWire EZ (Boston Scientific). †PercuSurge GuardWire (Medtronic).
NA not available.
Figure 1. Distal Balloon Occlusion Device
(A) The lesion is crossed with the GuardWire. (B) GuardWire balloon inﬂate
(C) Thereafter, the balloon is inﬂated until angiography shows no forward
distal protection. Image provided courtesy of Medtronic. ©2011 Medtronic or itsloon deflation and restoration of antegrade blood flow.
Several advantages are the low crossing profile and
entrapment of debris of all sizes as well as neurohumoral
mediators such as serotonin and thromboxane that may
have an adverse effect on the distal microvasculature. Its
disadvantages are: 1) the need to cross the lesion before
adequate protection, possibly liberating friable material
before balloon occlusion; 2) temporary cessation of blood
flow leading to ischemia and possible hemodynamic
instability, as well as limiting visualization making accu-
rate stent placement difficult; 3) inability to obtain full
evacuation, especially near the occlusion balloon; and 4)
possible traumatic injury to the SVG during balloon
occlusion. Distal lesions are not amenable to distal
balloon occlusion devices because a relatively disease-free
landing zone of approximately 3 cm distal to the lesion is
required for placement of the occlusion balloon.
The Food and Drug Administration (FDA)–approved
PercuSurge GuardWire (Medtronic, Minneapolis, Min-
nesota) consists of a 0.014-inch diameter wire with a
central lumen affixed to an inflatable distal occlusion
balloon (Fig. 2, Table 4). SAFER (Saphenous Vein Graft
ngioplasty Free of Emboli, Randomized Trial) (20)
emonstrated that it decreased the incidence of no-reflow
3.2% vs. 8.3%, p  0.005) and 30-day MACE (9.6% vs.
6.5%, p  0.004).
The TriActiv embolic protection system (Kensey Nash
orporation, Exton, Pennsylvania) differs from the Guard-
ire in that it has a flush catheter, which infuses heparin-
zed saline, attached to the balloon guidewire. The mixture
f saline, blood, and atheromatous debris is extracted
hrough the guiding catheter. PRIDE (A Prospective, Ran-
omized Controlled Trial of Distal Protection With the
percutaneous coronary intervention performed under distal protection.
aphenous vein graft (SVG) intervention can be performed with completed and
ﬂow. Safﬁliates. All rights reserved.
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837Kensey-Nash TriActiv System Compared to the GuardWire
or FilterWire) trial (62) reported that it was noninferior to a
control group of patients treated with either the GuardWire
and the FilterWire EZ (Boston Scientific) in terms of
30-day MACE (11.2% vs. 10.1%, p  0.65; p  0.02 for
noninferiority). However, the TriActiv system was associ-
ated with more vascular complications (10.9% vs. 5.4%, p
0.01) and the need for blood transfusion (7.7% vs. 3.5%,
p  0.02), perhaps in part because the procedure was
performed with larger caliber (8-F) guiding catheters.
Distal embolic ﬁlters. A distal filter system is composed of a
tightly wrapped filter attached to a guidewire and
sheathed within a delivery catheter for placement distal to
the target lesion (Fig. 3). It can trap debris that embolize
while the intervention is performed over the guidewire.
Upon completion, a retrieval catheter is advanced over
the guidewire to collapse the filter and remove it along
with retained contents.
Its advantages include the ease-of-use, maintenance of
antegrade blood flow during intervention to avoid ischemia
and the need for “hurried” PCI, and the ability to inject
Figure 2. PercuSurge GuardWire Distal Protection System
(A) A Microseal adapter controls a miniature valve within the hypotube and ke
balloons and stents are passed over the wire to perform percutaneous corona
occlusion balloon, which stops blood ﬂow to the distal microcirculation. (C) Th
eter removes debris while the occlusion is inﬂated. Image provided courtesy ocontrast media to facilitate accurate stent placement. It may Fbe preferred in patients who are undergoing high-risk
intervention and are at increased risk for hemodynamic
instability in instances of temporary SVG occlusion, such as
patients with severe left ventricular dysfunction, last remain-
ing conduit, and need for multiple stents. Disadvantages
include a high crossing profile (large diameter sheath
approximately 3- to 4-F), poor maneuverability, inability to
completely entrap microparticles and neurohumoral sub-
stances, possible occlusion of the filter due to large amounts
of debris, possible incomplete apposition of the filter, and
inability to use in very distal lesions because of the need for
a landing zone to deploy the filter.
The first FDA-approved filter was the FilterWire EX
(Boston Scientific). The FIRE (FilterWire EX Randomized
Evaluation) trial (63) showed similar MACE rates at 30
days (9.9% vs. 11.6%, superiority p  0.53, noninferiority
 0.0008) and 6 months (19.3 vs. 21.9%, p  0.44) (64)
ith the FilterWire EX and GuardWire plus system.
The BLAZE (Embolic Protection Transluminally with
he FilterWire EZ Device in Saphenous Vein Grafts)
egistry reported on the outcomes of the second-generation
he occlusion balloon inﬂated while standard interventional devices such as
rvention. A 0.014-inch nitinol-based hypotube guidewire inﬂates a (B) distal
Flator inﬂates the balloon to stop blood ﬂow. (D) The Export aspiration cath-
tronic. ©2011 Medtronic or its afﬁliates. All rights reserved.eps t
ry inte
e EZ-ilterWire EZ, which has a lower crossing profile compared
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838with the FilterWire EX (3.2-F vs. 3.9-F), an improved
delivery system with a retooled nose cone, greater filter
apposition of bends, and a smaller pore size (100 m vs. 110
m) (65). The device success rate was 97.8%, and 30-day
MACE was 6.7%, all due to non–Q-wave myocardial
infarction.
The SpideRx embolic protection device (ev3, Plymouth,
Minnesota) is also FDA-approved for SVG intervention. It
can cross the lesion using a conventional 0.014-inch guide-
wire, which may be beneficial in tortuous vessels. It is
subsequently inserted through a delivery sheath over the
guidewire. In the SPIDER (Saphenous Vein Graft Protec-
tion in a Distal Embolic Protection Randomized) trial, the
SpideRx nitinol filter was noninferior to the FilterWire and
the GuardWire (MACE: 9.1% vs. 8.4%, p  0.001 for
noninferiority) (66).
Another filter-based distal protection device, CardioShield
(MedNova Ltd., Galway, Ireland), did not demonstrate
noninferiority to the GuardWire. In the CAPTIVE (A
Table 4. 30-Day Outcomes of Selected Trials of
Embolic Protection Devices
MACE Death MI No-Reflow
SAFER
GuardWire 9.6 1.0 8.6 3
Control 16.5 2.3 14.7 9
p value 0.004 0.17 0.008 0.001
FIRE
FilterWire EX 9.9 0.9 9.0 NA
GuardWire 11.6 0.9 10.0 NA
p value 0.53 0.99 0.69 NA
BLAZE
FilterWire EZ 6.7 0 6.7 NA
PRIDE
TriActiv 11.2 1.3 9.9 NA
GuardWire/FilterWire EZ 10.1 0.6 8.8 NA
p value 0.65 0.45 0.64 NA
SPIDER
Spider 9.1 0.3 7.7* NA
GuardWire/FilterWire EZ 8.4 0.6 7.0* NA
p value 0.79 NS NS NA
PROXIMAL
Proxis 9.2 0.7 6.4* NA
Control 10.0 1.0 7.9* NA
p value 0.78 1.0 0.52 NA
Values are percentages. FilterWire is a product of Boston Scientific. GuardWire is a product of
Medtronic Inc. Proxis is a product of St. Jude Medical. Spider is a product of ev3. TriActiv is a
product of Kensey Nash. *Non–Q-wave MI.
BLAZE Embolic Protection Transluminally with the FilterWire EZ Device in Saphenous Vein
Grafts; FIRE FilterWire EX Randomized Evaluation; NS nonsignificant; PRIDEA Prospective,
Randomized Controlled Trial of Distal Protection With the Kensey-Nash TriActiv System Com-
pared to the GuardWire or FilterWire; PROXIMAL Proximal Protection During Saphenous Vein
Graft Intervention; SAFER Saphenous Vein Graft Angioplasty Free of Emboli, Randomized Trial;
SPIDER  Saphenous Vein Graft Protection in a Distal Embolic Protection Randomized; other
abbreviations as in Tables 1 and 2.Prospective, Randomized, Controlled Trial of Distal Pro-tection With the Third-Generation Mednova Emboshield
Compared to the GuardWire or FilterWire) (67), when
analyzing the data on a modified intention-to-treat, in the
noninferiority analysis, the 30-day MACE rate was signif-
icantly lower in patients treated with the GuardWire than in
patients treated with the CardioShield group (8.8 vs. 10.1%,
p  0.022).
Proximal balloon occlusion device. The FDA-approved
roxis embolic protection system (St. Jude Medical, Maple
roves, Minnesota) employs a distal balloon that seals the
nner sheath to the SVG while the proximal balloon seals
he inner sheath to the inside of the guiding catheter
Figs. 4 and 5). Proximal balloon occlusion creates a
tagnant column of blood suspending debris from emboli-
ing downstream into the microvasculature. After comple-
ion of the intervention, the blood containing the debris can
e aspirated with a suction catheter before deflating the
alloon and restoring blood flow. The advantages are that
he operator can use the guidewire of choice, protection
rom distal embolization of atheromatous debris can be
stablished before crossing the lesion, both particles and
asoactive substances can be retrieved downstream, side
ranches can be protected, and distal lesions that are not
menable to distal embolic protection because of lack of a
anding zone can be treated. The disadvantages are the
nability to use the device in ostial or very proximal lesions
s approximately 15 mm of disease-free segment proximal
o the target lesion is required, and the cessation of
ntegrade perfusion resulting in myocardial ischemia.
In the PROXIMAL (Proximal Protection During Sa-
henous Vein Graft Intervention) trial (68), the Proxis
evice demonstrated noninferiority to the FilterWire or
uardWire. At 30 days, MACE occurred in 10.0% of
ontrol and 9.2% of test patients; difference  0.8% (95%
I: 5.5% to 4.0%); p for noninferiority  0.006.
harmacological Treatment of Slow or No-Reflow
Compromise of the integrity of the microvascular flow can
lead to slow or no-reflow. Independent predictors for slow
or no-reflow in SVG intervention include probable throm-
bus (OR: 6.9; 95% CI: 2.1 to 23.9; p  0.001), acute
coronary syndromes (OR: 6.4; 95% CI: 2.0 to 25.3; p 
.003), degenerated SVG (OR: 5.2; 95% CI: 1.7 to 16.6;
 0.003), and lesion ulceration (OR: 3.4; 95% CI: 0.99 to
1.6; p  0.04) (16). Although convincing clinical trial
data are lacking, pharmacotherapy targeted at microvas-
cular flow with intragraft administration of vasodilators is
the mainstay of treatment for slow or no-reflow. Delivery
of pharmacotherapy to the distal microvasculature can be
maximized with a microcatheter like an aspiration throm-
bectomy catheter.
Adenosine. Adenosine is an endogenous purine nucleoside,
a vasodilator of arteries and arterioles, and inhibits platelet
s
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839activation and aggregation. Although severe bradycardia
may occur due to its effect on sinoatrial and atrioventricular
nodal conduction, the half-life of adenosine is very short
and these effects rarely last more than a few seconds.
Prophylactic administration of intragraft adenosine does not
appear to decrease the risk of slow or no-reflow, but it can
reverse slow or no-reflow with multiple boluses (69). In a
retrospective study of 143 patients, the incidence of slow or
no-reflow was similar in patients who received pre-
procedural administration of intragraft adenosine and those
who did not (14.2% vs. 13.6%, p  0.9). In patients who
developed slow or no-reflow, high doses of intragraft
adenosine (5 boluses of 24 g each) resulted in reversal of
low or no-reflow compared with low doses (5 boluses)
91% vs. 33%, p  0.02), and final Thrombolysis In
yocardial Infarction (TIMI) flow grade was significantly
mproved (2.7  0.6 vs. 2.0  0.8, p  0.04). Rapid,
igh-velocity injections of intragraft adenosine to reverse
low or no-reflow resulted in TIMI flow grade 3 in 91% of
ases (70).
Nitroprusside. Nitroprusside is a direct donor of nitric
oxide. In a study of 20 patients, 9 (45%) developed slow or
no-reflow after SVG intervention, intracoronary adminis-
Figure 3. FilterWire EZ
(A) The FilterWire is composed of a polyurethane ﬁlter basket pre-mounted on
m. (B) The FilterWire is compatible with a 6-F guiding catheter, has a crossin
and is available in wire lengths of 190 and 300 cm. A landing zone of 30 mm
ter. Image provided courtesy of Boston Scientiﬁc. ©2011 Boston Scientiﬁc Corptration of nitroprusside (median dose: 200 g) resulted insignificant and rapid improvement in both angiographic
flow (p  0.01 compared with pre-treatment angiogram)
and blood flow velocity (p  0.01 compared with pre-
treatment angiogram) (71). Nitroprusside was not asso-
ciated with significant hypotension or other adverse
clinical events in this study, but can cause profound
hypotension in patients who are volume depleted or
hypotensive at baseline.
Verapamil. Prophylactic intragraft administration of vera-
amil before SVG intervention tended to reduce the occur-
ence of no-reflow compared with placebo (0% vs. 33.3%,
 0.10), increased the TIMI frame count (53.3  22.4%
faster vs. 11.5  38.9%, p  0.016), and resulted in a trend
toward improved TIMI myocardial perfusion grade (72).
Intragraft verapamil (100 to 500 g) improved the flow in
ll 32 episodes of no-flow (TIMI flow grade 1.4  0.8 pre-,
o 2.8  0.5 post-intragraft verapamil, p  0.001) and
eestablished TIMI flow grade 3 in 88% of cases (73).
Nicardipine. Prophylactic intragraft administration of nicar-
dipine, a potent arteriolar vasodilator, was followed by direct
stenting for degenerated SVG without the use of a distal
protection device in 83 patients and resulted in a total
creatine phosphokinase 3 the upper limit of normal and
14-inch guidewire and pre-loaded on a delivery sheath. The pore size is 100
le of 3.2-F, can protect saphenous vein grafts 3.5 to 5.5 mm in diameter,
quired and a retrieval sheath is required for capture and removal of the ﬁl-
n or its afﬁliates. All rights reserved. PTFE  polytetraﬂuorethylene.a 0.0
g proﬁ
is reCK-MB 3 the upper limit of normal in 1.5% and 4.4%
saph
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840or patients, respectively (74). Slow or no-reflow occurred
transiently in 2.4% of patients. In-hospital MACE occurred
in 4.4%, and no additional MACE occurred from hospital
discharge to 30 days.
Figure 4. Proxis Proximal Embolic Protection Device
(A) Proximal embolic protection device can provide protection before crossing
proximal to the lesion, the balloon is inﬂated to suspend blood ﬂow in the SV
lesion. (D) Embolic debris is aspirated from the SVG after stenting. (E) The bal
Jude Medical. ©2011 St. Jude Medical or its afﬁliates. All rights reserved. SVG 
Figure 5. Proxis Proximal Embolic Protection Device
The CO2 inﬂation device is attached to the catheter and automatically inﬂates
syringe removes liberated debris before balloon deﬂation. Image provided cou
reserved.Conclusions
Long-term event-free survival after coronary artery bypass
surgery will continue to be limited as long as SVGs are used
esion with a guidewire. (B) After the Proxis is advanced into the target vessel
SVG intervention can be performed after a guidewire is advanced across the
deﬂated, restoring blood ﬂow in the SVG. Image provided courtesy of St.
enous vein graft.
roxis sealing balloon. Another button deﬂates the balloon. An aspiration
of St. Jude Medical. ©2011 St. Jude Medical or its afﬁliates. All rightsthe l
G. (C)
loon isthe P
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841as conduits for surgical revascularization. Percutaneous
SVG revascularization is a feasible treatment strategy, but
success is limited by high rates of periprocedural adverse
events (e.g., no-reflow, periprocedural myocardial infarc-
tion), intermediate-term restenosis, and SVG progression
outside of the treated segments. Embolic protection devices
are recommended by the American College of Cardiology/
American Heart Association guidelines to reduce peripro-
cedural complications during SVG intervention and should
be used whenever feasible to decrease the risk of distal
embolization. Pre-dilation with an undersized balloon may
improve procedural success by facilitating the delivery and
deployment of the embolic protection device. The optimal
pharmacological treatment for slow or no-reflow is unclear,
although a variety of vasodilators have shown promise.
Covered stents have failed to demonstrate clinical benefit in
reducing periprocedural myocardial infarction and resteno-
sis rates. Restenosis after SVG intervention is high with
BMS. Use of DES may decrease restenosis compared with
use of BMS, but confirmation from the ongoing large,
randomized, controlled clinical trials are necessary to dem-
onstrate the safety and efficacy of DES in SVGs. In general,
patient outcomes are optimized when coronary artery bypass
graft procedures are done without SVGs, although pan-
arterial revascularization is still the exception rather than the
rule. When diseased SVGs cause progressive ischemic
syndromes, PCI of the native coronary arteries should be
considered whenever possible.
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